What question did this study set out to answer?

The central aim is to assess how belimumab affects kidney function in patients with lupus nephritis.

April 18, 2026Open Access

Effect of belimumab on patients with lupus nephritis and impaired kidney function: post hoc subgroup analysis of the phase III BLISS-LN trial

Puntos clave

The central aim is to assess how belimumab affects kidney function in patients with lupus nephritis.
Post hoc subgroup analysis from the phase III BLISS-LN trial
Focus on patients with lupus nephritis and impaired kidney function
Evaluation of clinical outcomes related to kidney health
Belimumab showed potential benefits in kidney function improvement.
Observed reduction in symptoms like haematuria and proteinuria.
Indicated decrease in the risk of kidney failure in treated patients.

Resumen

Lupus nephritis (LN) is one of the most serious complications of SLE, manifesting as haematuria and/or proteinuria, hypertension and ultimately kidney failure.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Calatroni et al. (Thu,) studied this question.

synapsesocial.com/papers/69e31f7340886becb653ea52 https://doi.org/https://doi.org/10.1136/lupus-2025-001834

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar

Ver artículo completo